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Most major clinical trials in cardiology report time-to-event outcomes using the Cox proportional 
hazards model so that a treatment effect is estimated as the hazard ratio between groups, 
accompanied by its 95% confidence interval and a log-rank P-value. But non-proportionality of 
hazards (non-PH) over time occurs quite often, making alternative analysis strategies 
appropriate.  We present real examples of cardiology trials with different types of non-PH: an 
early treatment effect, a late treatment effect and a diminishing treatment effect. In such 
scenarios, we examine the relative merits of a Cox model, an accelerated failure time model, a 
milestone analysis and restricted mean survival time. We also present some post-hoc analyses for 
exploring any specific pattern of non-PH. We then make recommendations particularly regarding 
how to handle non-PH in pre-defined Statistical Analysis Plans, trial publications and regulatory 
submissions.  
 





Clinical trials in cardiovascular disease often involve a time-to-event outcome, whereby patients 
are followed up from randomisation until the occurrence of a cardiovascular event or the end of 
the study. In such trials, a hazard ratio estimated from a Cox proportional hazards model is often 
reported as the main measure of treatment effect. The hazard ratio can be interpreted as the ratio 
of the event rate at any given time in the treatment group relative to the control group, and in the 
Cox model is assumed to remain the same throughout the duration of the study. However, in 
some instances, particularly where experimental and control treatments are very different, this is 
unlikely to be true. For example, in surgical trials a more aggressive or invasive strategy is 
sometimes associated with a higher early procedural risk but a lower long-term risk.
1,2
 In drug 
trials, the effect of treatment may not materialize until several months, or even years after 
treatment initiation.
3,4
  Non-proportional hazards describes situations like these where the hazard 
ratio is not constant over time. In such cases, an overall hazard ratio may not be the most 
informative summary of the treatment effect and alternative methods of analysis may be more 
suitable. However, there is a lack of practical guidance as to the best methods to assess the 
proportional hazards assumption, and which methods to use for analysis for the various types of 
non-proportional hazards. We therefore applied several methods for analysis to four clinical 
trials in cardiovascular disease. We describe the types of non-proportional hazards that occur and 
discuss the pros and cons of each method. We conclude with a set of recommendations on how 
to prepare for and then tackle non-proportional hazards in future trials.  
 
METHODS 
Data. We used data from four clinical trials with time-to-event outcomes, chosen as key 
examples of the different types of treatment effects over time that can occur.   
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The ASCOT study (Anglo Scandinavian Cardiac Outcomes Trial) was a randomized trial 
evaluating two experimental treatments using a 2x2 factorial design.
5,6
  At baseline, 19,257 
patients were randomized to one of two anti-hypertensive treatments: an amlodipine-based 
regime or an atenolol based regime. This part of the trial is called the ASCOT blood-pressure 
lowering arm (ASCOT-BPLA)
6
 and our analysis of ASCOT-BPLA used the secondary endpoint 
of cardiovascular mortality.  A subset of 10,305 patients with non-fasting total cholesterol 
concentrations of at least 6.5 mmol/L were also randomized to either atorvastatin or placebo. 
This part of the trial is called the ASCOT lipid-lowering arm (ASCOT-LLA).
5
 Our analysis of 
ASCOT-LLA used the secondary endpoint of total coronary events.  
The CHARM program randomized 7,599 patients with chronic heart failure to candesartan or 
placebo therapy in three randomized trials assessing the impact of candesartan on time to first 
heart failure hospitalization or cardiovascular death.
7
 We analysed data from the CHARM-
Overall program, which included patients from all three trials, had a primary outcome of all-
cause death and a median follow-up of 3.1 years.  
The EXCEL trial randomized 1,905 eligible patients with left main coronary artery disease to 
either coronary artery bypass graft (CABG group) or percutaneous coronary intervention (PCI 
group) with fluoropolymer-based cobalt–chromium everolimus-eluting stents.
1
 The primary 
outcome, and the focus of our analyses was a composite outcome of death, stroke or myocardial 




Identifying non-proportional hazards  
To assess the proportional hazards assumption, Cox suggested that one can fit an interaction 
between the estimate of the (log) hazard ratio and time, with time modelled as a linear covariate.
8
  
We use this method to assess whether there is a statistically significant deviation from 
proportional hazards. An alternative is to compare the hazard ratio before and after a threshold 
time, i.e. by fitting an interaction between log hazard ratio and an indicator variable for time. 
This approach can have greater power to detect certain types of non-PH, but can increase the risk 
of falsely rejecting proportional hazards when the threshold time is chosen post-hoc. Several 
further methods (e.g. Grambsch-Therneau test) have been suggested for detection of non-PH, but 
none are clearly superior to using a time-treatment interaction variable.
9
 Graphically assessing 
the extent of non-proportional hazards can also be useful. There are several informative methods 
for this purpose
10
; we used plots of the smoothed scaled Schoenfeld residuals against follow-up 
time, which show a smoothed estimate of the log hazard ratio against follow-up time. If the 
proportional hazards assumption is true then the underlying log-hazard ratio is constant over 
time, and so we expect the plot to show an approximately horizontal line. 
Estimation methods 
We used four statistical methods for the estimation of the overall treatment effect. They are 
summarised in the Central Illustration and illustrated in Figure 1. Our first analysis used the Cox 
proportional hazards model to estimate the hazard ratios associated with treatment.  
Our second analysis used an accelerated failure time model to estimate time ratios associated 
with treatment. The time ratio describes the estimated delay until an event occurs with treatment 
relative to control. For example, a time ratio of 2 would mean that the time until an event occurs 
is twice as long in the treatment group relative to control, everything else being equal. There are 
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several types of accelerated failure time models; we used the log-logistic model for the baseline 
hazard function, because unlike some other models (e.g. exponential) it is not restricted to 
proportional hazards.   
Our third analysis estimated the difference in the percentage of patients with an event in the 
treatment group compared to the control group at a fixed time since baseline, known as the 
milestone time. We refer to this analysis as a milestone analysis. The percentage of patients with 
an event in each group was estimated using the Kaplan-Meier method, and the Greenwood 
formula was used to estimate standard errors. This method is similar to using logistic regression 
or calculating the odds ratio associated with treatment, but also accounts for loss to follow-up. 
The choice of milestone time is an important aspect in such analyses. In ASCOT-LLA, CHARM 
and EXCEL we chose a milestone time of 3 years, close to the median follow-up times in each of 
these studies (3.3 years, 3.1 years and 3.0 years respectively). A milestone time of 5.5 years was 
chosen in ASCOT-BPLA (median follow-up 5.5 years).  
Our fourth analysis estimated the difference in restricted mean survival time (RMST 
difference) between groups, up until a fixed milestone time. Survival here refers to event-free 
survival, i.e. the absence of an outcome event, rather than simply continuing to be alive. The 
RMST in each group refers to the mean time spent free from an outcome event in each group up 
until the milestone time, after adjusting for loss to follow-up. The RMST difference can be 
represented as the difference in areas under the Kaplan-Meier plots for each group (Figure 1). 
Following the advice of Royston & Parmar,
11
 we modelled event-free survival separately in each 
of the treatment and control groups using a flexible parametric survival model with 3 degrees of 
freedom (except in the EXCEL study wherein we used 2 degrees of freedom in order to achieve 






For each method, we estimated the appropriate treatment effect, its 95% confidence interval and 
a p-value from the corresponding hypothesis test.  
In addition, we used some methods more suitable for post-hoc analyses. We used piecewise 
hazards models, whereby time since baseline was split into segments, and hazard ratios were 
calculated separately for each period of time by applying a Cox-proportional hazards model 
within each period.  
Finally, we assessed the number of patients that would be required to achieve 80% power under 
each analysis method, assuming the observed time pattern of treatment difference is the truth. It 
is known that the standard error of each estimated treatment effect is approximately inversely 
proportional to the square root of the sample size. By using this relationship and the estimated 
standard error from each analysis it was possible to calculate the approximate sample size 
required to achieve 80% power (see Supplementary Appendix for further details).  Analyses 
were done in Stata 15.1; flexible parametric models were implemented in the stpm2 package.  
 
RESULTS 
The cumulative incidence of events in each treatment group is shown for each of the four studies 
in Figure 2, with the pattern of treatment effect appearing to differ in each study. In ASCOT-
LLA (Figure 2a) there was a steady divergence between cumulative incidence curves over time. 
This pattern is typical when proportional hazards is a reasonable assumption. ASCOT-BPLA 
(Figure 2B) showed a slightly different pattern. The cumulative incidence curves in each group 
were very similar for the first 2.5 years of follow up, and then gradually diverged, an example of 
a delayed treatment effect.  Conversely, in CHARM (Figure 2c), the cumulative incidence curves 
diverged very early during follow up but then ran parallel to one another after 6 months. This 
pattern is referred to as an early effect. Finally, in EXCEL (Figure 2d), the curves diverged early 
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on, but the early effect of treatment was not maintained, with the cumulative incidence curves 
converging later; a pattern we term a diminishing treatment effect.  
We applied each of our estimation methods to each of these four studies.  
ASCOT-LLA. In the ASCOT-LLA study total coronary events were compared amongst patients 
receiving atorvastatin or placebo. The treatment effect observed was consistent with proportional 
hazards; there was an approximately horizontal line throughout follow-up in the plot of 
Schoenfeld residuals and the test for a treatment-time interaction was non-significant (p=0.90, 
Supplementary Figure 1).  
We found a statistically significant reduction in total coronary events regardless of the method 
used for analysis (Table 1). The hazard ratio of 0.71 from a Cox proportional hazards model and 
the time ratio of 1.51 from an accelerated failure time model have very similar interpretations. In 
the former the hazard for coronary events is 29% lower with atorvastatin and in the latter the 
time until a coronary event is delayed by 51%. In the milestone analysis, the 3-year event rate 
was 1.3% lower with atorvastatin and the RMST difference estimated that on average a patient 
was event-free 7.6 days longer with atorvastatin in the 3 years after randomization.  
Note both the milestone analysis and RMST difference estimate an absolute effect of treatment 
whereas the Cox and accelerated failure time models estimate a relative effect (hazard ratios or 
time ratios, respectively). However, when the proportional hazards assumption is valid, 
milestone analysis and RMST have disadvantages. Data collected after the milestone time is 
ignored, resulting in a loss of power, and so more patients would be required in a trial using these 
methods as the primary analysis (Table 2). In addition, the choice of milestone time is somewhat 
arbitrary.  
ASCOT-BPLA. Amlodipine was compared to atenolol in the ASCOT-BPLA trial. There was 
clear evidence of non-proportional hazards (p=0.0013; Supplementary Figure 1). A highly 
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significant reduction in cardiovascular death was seen with all methods except for RMST.  The 
hazard ratio comparing amlodipine to atenolol was 0.76 (p=0.0012), the time ratio was 1.29 
(p=0.0010) and the estimated reduction cardiovascular deaths by 5.5-year was 0.8% (p=0.0019) 
(Table 1). However, the estimated RMST difference of 2.9 days was not statistically significant 
(p=0.31). When a delayed treatment effect is present, there is a large reduction in statistical 
power if RMST is chosen as the primary analysis, so that a trial using RMST would require 
many more patients than a trial using any of the other methods (Table 2). This is due to the lack 
of benefit in the early period of follow-up, and occurs despite less than 6% of total patient 
follow-up occurring after the milestone time.  Additionally, while the RMST difference of 2.9 
days seems like a small difference, a careful interpretation is warranted because it is plausible 
that the differences in event-free survival would continue to accrue beyond the milestone time. 
For example, suppose we were to take a longer-term perspective and consider RMST difference 
at 10 years. Suppose also that the risk of cardiovascular deaths between 5.5 years and 10 years 
were the same in both groups so that there is no further benefit or harm related to treatment after 
the milestone time. We would then expect the cumulative incidence curves for each group to run 
approximately parallel to one another between 5.5 and 10 years. The RMST difference (which 
can be visualised as the area between the cumulative incidence curves) would therefore continue 
to accrue and would be greater at 10 years than it was at 5.5 years (~16.2 days vs. 2.9 days; 
Supplementary Figure 2).  
CHARM. In the CHARM-Overall study, in which the effect of candesartan was compared with 
placebo on all-cause death, there was strong evidence against proportional hazards (p-value for 
treatment-time interaction=0.009). There was an apparent early effect that lasted only for the first 
6-18 months following randomisation (Figure 2c, Supplementary Figure 1). The evidence against 
proportional hazards was even stronger when comparing the HR before 6 months to the HR 
thereafter (0.59 vs 1.00, p-value for interaction=0.0001). In analyses of the effect of candesartan 
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on mortality the p-value was close to 0.05 for all methods except for the RMST difference where 
there was strong evidence that mean 3-year survival was longer with candesartan (21.0 days, 
p=0.0008). The Cox model (hazard ratio 0.91, p=0.055) failed to demonstrate a treatment 
benefit, whereas results from an accelerated failure model (time ratio 1.11, p=0.032) and a 
milestone analysis (1.95% 3-year reduction in deaths, p=0.044) were both just statistically 
significant. RMST difference will generally be more statistically powerful than the other 
methods with an early treatment effect (Table 2). In general, any treatment difference in early 
events has a greater influence on the RMST difference than events occurring later. This can be 
visualised by considering the Kaplan-Meier plot in Figure 2c, in which a gap between the curves 
opens up before 6 months and the area between the two curves continues to accumulate with 
time. In contrast, the relative importance of early and late events is broadly similar with the other 
three methods so that the similar event rate later in follow-up had a greater diluting influence on 
the apparent early treatment benefit.  
Data from the CHARM study also demonstrate the sensitivity of findings to the choice of 
milestone time. Although there was some evidence of a difference in 3-year survival, had we 
chosen a different milestone time, for example 34 months or 38 months the difference would not 
have been statistically significant (p=0.093 and p=0.096 respectively). On the other hand, if one 
takes a short-term perspective with the milestone set at 6 months, then the mortality difference is 
highly significant (4.9% vs 2.9%, p<0.0001). It is also worth noting that for treatment effects that 
decrease over time, the exclusion of data after the milestone time does not lead to a loss in 
statistical power, because including later deaths would further dilute the significance of the early 
treatment effect.  
EXCEL. The EXCEL study compared a composite outcome of stroke, MI or death in patients 
with left main coronary artery disease treated with PCI or CABG. There was a much higher 
procedural risk of the composite outcome with CABG (7.9% within 30 days) compared to PCI 
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(4.9%), but by 3-years the proportions of patients with the composite outcome were similar for 
CABG (14.7%) and PCI (15.4%) (Figure 2d). Unsurprisingly therefore, there was very strong 
evidence against the proportional hazards assumption with the estimated log hazard ratio 
differing markedly over follow-up (p for treatment-time interaction=0.003, Supplementary 
Figure 1). 
None of the main methods for estimation demonstrated a clear treatment benefit for either 
intervention, although there were notable differences between the methods. Results from a Cox 
model (hazard ratio for PCI vs CABG: 1.01, p=0.97) or from an accelerated failure time model 
(time ratio: 1.06, p=0.88) do not provide much insight. Naively interpreted, these estimates 
appear to indicate a lack of difference between groups, whereas the two treatments clearly differ 
in the timing of the risk of outcomes occurring with each intervention. The underlying 
assumption of proportional hazards used in a Cox model and assumption of a constant time ratio 
in the accelerated failure time model were clearly not satisfied (treatment-time interaction 
p<0.001 for both). The milestone analysis at 3 years for the percentage with the primary outcome 
(treatment difference +0.5%, 95% CI -2.7% to 3.7%) is readily interpreted and does not make 
any modelling assumptions, but it does not take into account the difference in the timing of 
events during follow-up. The RMST difference is perhaps the most useful of the four methods 
for summarising the data from the EXCEL study. It takes into account the fact that although the 
total number of events was similar in the two groups, they tended to occur later in the PCI group 
thereby lengthening the time a patient was event-free.  The estimated gain in event-free survival 
up to 3 years is 18.3 days (95% CI, -11.1 days, 47.8 days), but the difference is not statistically 
significant.  
In order to further understand the results from EXCEL, we performed 3 sets of post-hoc 
analyses. First, because the primary outcome was a composite of clinically heterogeneous events, 
we present cumulative incidence curves separately for each component (Supplementary Figure 
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3). We find that the lower procedural risk with PCI is largely due to a reduction in MI and stroke, 
rather than death. If considered alongside the patterns of the individual events through time, this 
analysis may be helpful in suggesting how future event rates might differ in the two groups. For 
example, it may suggest whether future Kaplan-Meier curves will continue to converge, 
crossover or progress in parallel. In a second analysis we used piecewise hazards models, where 
we split follow-up time into three segments representing procedural, mid-term and long-term 
follow-up, calculating hazard ratios separately within each segment. The hazard ratios for PCI 
versus CABG were 0.61 (95% CI 0.42 to 0.88) within 30 days of randomisation, 1.05 (95% CI, 
0.64 to 1.70) from 30 days to 1 year, and 1.93 (95% CI, 1.25 to 2.97) from 1 year to 3 years 
(Figure 3a). This simple approach can provide useful insight into the underlying patterns of risk. 
In a third approach, we generated additional diagnostic graphical displays (Figures 4b & 4c). 
Figure 3b shows the difference in event-free survival estimates and 95% confidence intervals 
throughout follow-up, equivalent to performing a milestone analysis at each day during follow 
up. This visually demonstrates that the early benefit of PCI is gradually eroded over time by an 
increased post-procedural risk. Figure 3c shows the difference in mean event-free survival time 
over study follow-up. The upward trend of the curve shows that the early benefit due to reduced 
procedural PCI risk has an effect on RMST out to nearly 3 years. For any choice of milestone 
time in the range up to 2 years the treatment difference in RMST is statistically significant. The 
greater number of primary events after PCI thereafter reduces the apparent benefit, whilst the 
confidence interval increases in width so that the treatment effect is no longer statistically 
significant.  
One caution in all these post-hoc analyses is that no correction is made for multiple testing, as 




For clinical trials of time-to-event outcomes, it has become standard practice to use Cox 
proportional hazards models both for trial design (e.g. power calculations) and statistical 
analysis. However, this may not be the best approach when the effect of treatment varies over 
time. Our analyses of four major cardiology trials demonstrate some alternative approaches, and 
outline some of their advantages and disadvantages under various patterns of treatment effect.  
When proportional hazards are satisfied, the Cox PH model is the most statistically powerful 
method, and hazard ratios are readily understood by clinicians. We therefore see little practical 
reason to use alternative analysis strategies as the pre-specified primary analysis when deviation 
from PH is not expected, despite recent critiques of the hazard ratio for estimating treatment 
effects.
13
 However, when major deviations are anticipated, it may be possible to adapt the design. 
In studies where an early treatment effect is anticipated, it may be possible to recruit fewer 
patients whilst maintaining adequate power by using RMST differences as the primary method 
of analysis rather than the Cox model. In contrast, when a delayed treatment effect is likely 
RMST difference is best avoided. In addition, with a delayed effect the sample size may need be 
inflated to allow for the extra variability caused by events occurring at the beginning of the trial 
when there is no difference between treatment groups, as was done in the CORONA trial of 
rosuvastatin.
14
    
In most cases the type of treatment effect is unknown in advance but the analysis method needs 
to be pre-specified. Unfortunately, there is no clear “best” method across all types of treatment 
effect. Although we are aware of several tests-based methods that maintain good statistical 
power to detect differences between treatments across a range of types of non-PH,
15,16
 these 
methods only provide a p-value without an accompanying estimation method linked to the test. 
An example is a test based on a series of weighted log-rank tests, where some of the tests 
counter-intuitively weight events occurring later in follow-up as more important than those 
occurring earlier.
16
 The p-value from such tests is informative only in that it shows that the 
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pattern of survival differs between treatment groups; it does not identify which treatment is 
“better” nor does it quantify how the difference between groups affects patient outcomes. 
Therefore, we do not recommend methods based only on hypothesis testing.  
Non-PH can have important implications for trial design beyond the choice of analysis strategy. 
When treatment is associated with a lower (or higher) short-term risk which later reverses, it is 
important that the trial continues for sufficient duration so that the long-term effects of the 
treatment can be fully understood.  Longer-term (i.e. 5-year) results from the EXCEL study will 
therefore be helpful to further understanding of the risks and benefits of PCI relative to CABG in 
patients with left main coronary disease. A second implication for trial design is that the stopping 
criteria used by data monitoring committees should take into account potential non-PH patterns 
of treatment effect. For instance, the CHARM program DSMB did not recommend stopping 
early even though a planned interim analysis of short-term mortality showed a highly significant 
reduction in mortality on candesartan.
17
 Conversely, caution would be required when stopping a 
trial early for futility if a delayed effect was anticipated.   
Post-hoc analyses of trials with non-PH can sometimes provide useful insights. A first step is to 
assess whether the proportional hazards assumption is reasonable. Using graphical displays such 
as scaled Schoenfeld residuals can help determine whether a single hazard ratio captures the 
effect of treatment with a reasonable degree of accuracy across the entire follow-up period.  
Formal statistical testing of proportional hazards is sometimes useful, but such tests can miss 
clinically important deviations from proportional hazards in small studies while detecting 
clinically unimportant deviations from proportional hazards in very large studies.   
When the proportional hazards assumption is not reasonable, using a piecewise hazards model 
can be useful. In our analysis of EXCEL it helped identify periods during which the hazard with 
PCI was less than, similar to, or greater than the risk with CABG. A limitation of this 
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methodology is that the post-hoc selection of time periods that appear visually different may 
exaggerate the real differences in hazard ratios over time. The hazard ratios calculated for later 
time periods also only include survivors of earlier time periods, and so are not truly randomised 
comparisons. A further post-hoc analysis not considered here is to explore whether non-PH has 
arisen by the combination of clinically distinct subgroups of patients in whom the effect of 
treatment is different. It is possible to have non-PH overall even though the PH assumption is 
satisfied within subgroups. Examples where this may have occurred are present in the medical 
literature
18,19
, although we are unaware of any convincing examples in cardiovascular trials to 
date. In such scenarios, subgroup analyses and/or stratified Cox proportional hazards models 
may be useful.  
One major concern is how one incorporates potential non-PH into the predefined statistical 
analysis plan for a major trial. It can be hard to anticipate the existence and pattern of non-PH in 
a trial, so in most circumstances the Cox PH model and associated log-rank test will be the 
predefined primary analysis. However, we would encourage SAPs to document contingency 
plans for an alternative primary analysis should clear evidence of non-PH be detected when the 
trial is unblinded for the final analysis. For instance, if clear evidence of a pattern of early 
treatment effect is reported, then the PH assumption is violated. An analysis using RMST could 
then be performed (as could have been applied to the CHARM program). Another example is in 
a meta-analysis of trials for oseltamivir treatment in influenza, where the pre-defined intent of 
Cox models was replaced by accelerated failure time models, since the former did not “fit the 
data” whereas the latter did.
20
 However, if not pre-specified, to change the primary analysis 
methodology of the primary outcome in light of lack of model fit is a radical step. Further debate 
is needed as to when such a step is truly acceptable in the primary publication and/or regulatory 
submission of a major clinical trial, and how this can be done in a way that does not result in an 
increased probability of false positive findings. A key question is “how great does the departure 
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from the PH assumption need to be?” in order to replace the focus on a Cox PH model with 
emphasis on an alternative more appropriate technique. 
Our review has limitations. First, with only one study for each pattern of treatment effect, the 
generalisability of our study may be questioned. However, our analyses are meant to be 
illustrative, with some of the findings, for example those relating to the power of RMST relative 
to a Cox model under various patterns of treatment effect, already established in the statistical 
literature.
21
 Second, we did not present data on a fifth type of treatment effect, wherein the 
Kaplan-Meier curves cross during follow-up (“crossover pattern”), as was observed in the 
STICH trial of CABG versus medical therapy.
22
 In such situations, a single effect estimate is 
unlikely to accurately capture the effect of treatment so the choice of appropriate statistical 
analyses would require careful consideration. One would need to consider the relative 
importance of later versus earlier events, and ensure that the study continues for long enough to 
allow a full understanding of the effect of treatment over time.  
In conclusion, serious attention needs to be given to appropriate analysis strategies when non-PH 
are evident in time-to-event outcomes. It is important to detect the type of non-PH that is present 
and select the analytical technique most appropriate to that situation. The consequences for more 
thorough Statistical Analysis Plans, trial publications and regulatory submissions need a further 
collective clarity of thought.   
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Accelerated failure time 
model 
Milestone analysis 
Restricted mean survival 
time (RMST) 
Effect measure Hazard ratio Time ratio 
Difference in proportion 
with event at milestone 
time 
Difference in event-free 
survival up to milestone 
time 
Improved survival when 
effect measure 
<1 >1 <0  >0  
Pros 
Uses all study data 
Powerful with proportional 
hazards 
Uses all study data 
Powerful with a constant 
time ratio 
No assumptions required 
No assumptions required 
Powerful for early 
treatment effect 
Cons 
Lacks power for early 
effects 
May be difficult to 
interpret or uninformative  
when assumptions not met 
Lacks power for early 
effects 
May be difficult to 
interpret or uninformative  
when assumptions not met 
Data after milestone time 
ignored 
 
Data after milestone time 
ignored 
Lacks power for delayed 
effects 
 
Recommended with     
Proportional hazards    + / - + / - 
Early effect + / - + / - + / -  
Delayed effect + / - + / - + / -  
Diminishing effect     
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Table 1. Results of main estimation methods. 
Study Treatments compared Outcome studied Cox proportional hazards Accelerated failure time Milestone analysis* 
Restricted mean survival time* 
(RMST) 








frequency of event 
(95% CI), % 
P-value 
Difference in RMST 
(95% CI), in days 
P-value 
ASCOT lipid lowering  Atorvastatin vs Placebo Total coronary events 0.71 (0.59 to 0.86) 0.00058 1.51 (1.19 to 1.92) 0.00067 -1.29 (-2.06 to -0.52) 0.00096 7.6 (2.5 to 12.7) 0.0037 
ASCOT BP lowering 
Amlodipine vs 
Atenolol 
Cardiovascular death 0.76 (0.65 to 0.90) 0.0012 1.29 (1.11 to 1.50) 0.001 -0.79 (-1.29 to -0.29) 0.0019 2.86 (-2.62 to 8.35) 0.31 
CHARM  Candesartan vs Placebo All-cause death 0.91 (0.83 to 1.00) 0.055 1.11 (1.01 to 1.21) 0.032 -1.95 (-3.85 to -0.05) 0.044 21.0 (8.7 to 33.4) 0.00084 
EXCEL  PCI vs CABG Death, stroke or MI 1.01 (0.80 to 1.28) 0.97 1.06 (0.50 to 2.26) 0.88 0.48 (-2.76 to 3.72) 0.77 18.3 (-11.1 to 47.8) 0.22 
*Milestone and restricted mean survival time were performed at 3 years in the ASCOT-LLA, CHARM and EXCEL studies, and 5 years in the ASCOT-BPLA trial. 
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Table 2. Number of patients required to provide 80% power for each method, assuming the same pattern of survival observed in each 
study  
 
  Patients required for 80% power using each analysis method* 
Study Patients actually 











10305 6825 6987 7416 9579 
ASCOT-BP 
lowering* 
19,257 13,948 14,484 15,743 >100,000 
CHARM 7599 16,208 12,964 14678 5350 
EXCEL 1905 >100,000 >100,000 >100,000 10,068 




Figure 1. Illustration of how each of the four primary analysis strategies relate to the Kaplan-Meier cumulative incidence curves. 
23 
 




Figure 3: Hazard ratios from piecewise hazards models (A), difference in 
probability of event-free survival over time (B), and difference in restricted 




In panels B and C, the solid blue line represents the estimate and the black dashed 
lines are 95% confidence intervals.   
 




